Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CPA1 | P15085 | 2/20 | 0.44 |
| ▸ | CPB1 | P15086 | 1/20 | 0.44 |
| ▸ | CPA3 | P15088 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4902613 | 1.00 | ALDH1A1 (0.56) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL28088843 | 1.00 | ALDH1A1 (0.56) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| Ammonia Solution, Strong SCHEMBL11785845 | 0.98 | ALDH1A1 (0.55) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL19224102 | 0.88 | ALDH1A1 (0.59) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL4908107 | 0.88 | ALDH1A1 (0.59) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL9636201 | 0.88 | ALDH1A1 (0.58) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL27981610 | 0.85 | ABCB1 (0.53) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL27769184 | 0.85 | ALDH1A1 (0.51) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL265561 | 0.84 | ALDH1A1 (0.58) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL7933968 | 0.84 | ALDH1A1 (0.58) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920044-B2 | Selective androgen receptor modulators | RADIUS PHARMACEUTICALS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20150322059-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH, INC. | 2015-11-12 | — | — | US | disclosed |
| US-9133182-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20130217732-A1 | Selective Androgen Receptor Modulators | RADIUS HEALTH, INC. | 2013-08-22 | — | — | US | disclosed |
| US-20080103311-A1 | Retroviral protease inhibitors | PHARMACIA CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
| US-7312333-B2 | Retroviral protease inhibitors | PHARMACIA CORPORATION (US) | 2007-12-25 | — | — | US | disclosed |
| US-20060166895-A1 | Retroviral protease inhibitors | MONSANTO COMPANY (NOW NAMED PHARMACIA CORPORATION, WHICH IS A WHOLLY OWNED SUBSIDIARY OF PFIZER, INC (US) | 2006-07-27 | — | — | US | disclosed |
| US-7026485-B2 | Retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-04-11 | — | — | US | disclosed |
| US-7026333-B1 | Retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20060040974-A1 | Retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-02-23 | — | — | US | disclosed |
| EP-1148050-A1 | Retroviral protease inhibitors | MONSANTO COMPANY (US) | 2001-10-24 | — | — | EP | disclosed |
| EP-0641325-B1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO CO (US) | 2001-03-07 | — | — | EP | disclosed |
| US-6180646-B1 | PREVENT REPRODUCTION OF RETROVIRUS | MONSANTO COMPANY | 2001-01-30 | — | — | US | disclosed |
| EP-0957093-A2 | Retrovial protease inhibitors | MONSANTO COMPANY (US) | 1999-11-17 | — | — | EP | disclosed |
| US-5948790-A | VIRICIDES | MOSANTO COMPANY (US) | 1999-09-07 | — | — | US | disclosed |
| US-5756534-A | Retroviral protease inhibitors | MONSANTO COMPANY (US) | 1998-05-26 | — | — | US | disclosed |
| US-5648364-A | HETEROCYCLIC PEPTIDE COMPOUNDS AS ENZYME INHIBITORS | MONSANTO COMPANY (US) | 1997-07-15 | — | — | US | disclosed |
| US-5643924-A | Retroviral protease inhibitors | MONSANTO COMPANY OF ST. LOUIS (US) | 1997-07-01 | — | — | US | disclosed |
| EP-0641325-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1995-03-08 | — | — | EP | disclosed |
| WO-1993023379-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322059-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | AR, SHBG, GPR119 | ALDH1A1 1277/4885TDP1 4352/4885MAPK1 1607/4885 |
| US-20080103311-A1 | Retroviral protease inhibitors | PREP, DNPEP, SERPINB1 | ALDH1A1 2859/4885TDP1 895/4885MAPK1 3128/4885 |
| US-20060040974-A1 | Retroviral protease inhibitors | PREP, TMPRSS15, DNPEP | ALDH1A1 2626/4885TDP1 574/4885MAPK1 2527/4885 |
| US-20130217732-A1 | Selective Androgen Receptor Modulators | AR, SHBG, GPR119 | ALDH1A1 1277/4885TDP1 4352/4885MAPK1 1607/4885 |
| US-20060166895-A1 | Retroviral protease inhibitors | MME, PREP, TMPRSS15 | ALDH1A1 2763/4885TDP1 554/4885MAPK1 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.